Patrick James Orme

Array ( [id] => 7219344 [patent_doc_number] => 20050260578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-11-24 [patent_title] => 'Antisense modulation of cellular apoptosis susceptibity gene expression' [patent_app_type] => utility [patent_app_number] => 10/415198 [patent_app_country] => US [patent_app_date] => 2001-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24813 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0260/20050260578.pdf [firstpage_image] =>[orig_patent_app_number] => 10415198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5789579 [patent_doc_number] => 20020161211 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-31 [patent_title] => 'Compositions, methods and kits relating to REMODELIN' [patent_app_type] => new [patent_app_number] => 10/045992 [patent_app_country] => US [patent_app_date] => 2001-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 52570 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0161/20020161211.pdf [firstpage_image] =>[orig_patent_app_number] => 10045992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7355071 [patent_doc_number] => 20040048820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-03-11 [patent_title] => 'Modulation of the transcription of pro-inflammatory gene products' [patent_app_type] => new [patent_app_number] => 10/398592 [patent_app_country] => US [patent_app_date] => 2003-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 8407 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0048/20040048820.pdf [firstpage_image] =>[orig_patent_app_number] => 10398592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 263786 [patent_doc_number] => 07569551 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-08-04 [patent_title] => 'Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides' [patent_app_type] => utility [patent_app_number] => 09/967726 [patent_app_country] => US [patent_app_date] => 2001-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 5223 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/569/07569551.pdf [firstpage_image] =>[orig_patent_app_number] => 09967726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6378451 [patent_doc_number] => 20020119570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-08-29 [patent_title] => 'Targeted gene correction by single-stranded oligodeoxynucleotides' [patent_app_type] => new [patent_app_number] => 09/962628 [patent_app_country] => US [patent_app_date] => 2001-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 12599 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0119/20020119570.pdf [firstpage_image] =>[orig_patent_app_number] => 09962628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7224712 [patent_doc_number] => 20040072776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-04-15 [patent_title] => 'Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy' [patent_app_type] => new [patent_app_number] => 10/380195 [patent_app_country] => US [patent_app_date] => 2003-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 3705 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0072/20040072776.pdf [firstpage_image] =>[orig_patent_app_number] => 10380195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 750826 [patent_doc_number] => 07022832 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-04-04 [patent_title] => 'Oligonucleotides containing an antisense sequence stabilized by a secondary structure, pharmaceutical compositions containing them and method of blocking gene expression using them' [patent_app_type] => utility [patent_app_number] => 09/949134 [patent_app_country] => US [patent_app_date] => 2001-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 35 [patent_no_of_words] => 9748 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/022/07022832.pdf [firstpage_image] =>[orig_patent_app_number] => 09949134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6778122 [patent_doc_number] => 20030049203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-03-13 [patent_title] => 'Targeted nucleic acid constructs and uses related thereto' [patent_app_type] => new [patent_app_number] => 09/945166 [patent_app_country] => US [patent_app_date] => 2001-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 20677 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0049/20030049203.pdf [firstpage_image] =>[orig_patent_app_number] => 09945166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 864853 [patent_doc_number] => 07368436 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2008-05-06 [patent_title] => 'TRPM-2 antisense therapy' [patent_app_type] => utility [patent_app_number] => 09/944326 [patent_app_country] => US [patent_app_date] => 2001-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 4855 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/368/07368436.pdf [firstpage_image] =>[orig_patent_app_number] => 09944326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6674835 [patent_doc_number] => 20030060438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-03-27 [patent_title] => 'Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof' [patent_app_type] => new [patent_app_number] => 09/930503 [patent_app_country] => US [patent_app_date] => 2001-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 25558 [patent_no_of_claims] => 137 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0060/20030060438.pdf [firstpage_image] =>[orig_patent_app_number] => 09930503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6538256 [patent_doc_number] => 20020137210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-09-26 [patent_title] => 'Method for modifying genetic characteristics of an organism' [patent_app_type] => new [patent_app_number] => 09/913040 [patent_app_country] => US [patent_app_date] => 2001-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 2643 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0137/20020137210.pdf [firstpage_image] =>[orig_patent_app_number] => 09913040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 630568 [patent_doc_number] => 07132529 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-11-07 [patent_title] => 'Antisense modulation of stearoyl-CoA desaturase expression' [patent_app_type] => utility [patent_app_number] => 09/918187 [patent_app_country] => US [patent_app_date] => 2001-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25774 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/132/07132529.pdf [firstpage_image] =>[orig_patent_app_number] => 09918187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7555122 [patent_doc_number] => 08067022 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-11-29 [patent_title] => 'Therapeutic inhibitor of vascular smooth muscle cells' [patent_app_type] => utility [patent_app_number] => 09/910388 [patent_app_country] => US [patent_app_date] => 2001-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 29 [patent_no_of_words] => 40473 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/067/08067022.pdf [firstpage_image] =>[orig_patent_app_number] => 09910388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1024802 [patent_doc_number] => 06884787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2005-04-26 [patent_title] => 'Antisense modulation of transforming growth factor-beta 3 expression' [patent_app_type] => utility [patent_app_number] => 09/906158 [patent_app_country] => US [patent_app_date] => 2001-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26855 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/884/06884787.pdf [firstpage_image] =>[orig_patent_app_number] => 09906158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 586917 [patent_doc_number] => 07442788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2008-10-28 [patent_title] => 'Antisense molecules and method of controlling expression of gene function by using the same' [patent_app_type] => utility [patent_app_number] => 10/311386 [patent_app_country] => US [patent_app_date] => 2001-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 35 [patent_no_of_words] => 34377 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/442/07442788.pdf [firstpage_image] =>[orig_patent_app_number] => 10311386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 92234 [patent_doc_number] => 07732417 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-06-08 [patent_title] => 'Methods and compositions for RNA interference using recombinant Dicer and Argonaut' [patent_app_type] => utility [patent_app_number] => 09/858862 [patent_app_country] => US [patent_app_date] => 2001-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 52 [patent_no_of_words] => 19150 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/732/07732417.pdf [firstpage_image] =>[orig_patent_app_number] => 09858862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5710974 [patent_doc_number] => 20060052319 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2006-03-09 [patent_title] => 'Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes' [patent_app_type] => utility [patent_app_number] => 09/825489 [patent_app_country] => US [patent_app_date] => 2001-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11487 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A9/0052/20060052319.pdf [firstpage_image] =>[orig_patent_app_number] => 09825489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5710974 [patent_doc_number] => 20060052319 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2006-03-09 [patent_title] => 'Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes' [patent_app_type] => utility [patent_app_number] => 09/825489 [patent_app_country] => US [patent_app_date] => 2001-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11487 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A9/0052/20060052319.pdf [firstpage_image] =>[orig_patent_app_number] => 09825489 [rel_patent_id] =>[rel_patent_doc_number] =>)